{"title":"Current Status and Future Trends in Myocarditis Related to the COVID-19 Vaccines: A Visual and Bibliometric Analysis.","authors":"Youao Zhang, Mengjia Wang, Jieyan Wang","doi":"10.2174/0115701611287623250107074054","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study aims to conduct a bibliometric and visual analysis of published studies on myocarditis and coronavirus disease 2019 (COVID-19) vaccines.</p><p><strong>Background: </strong>The widespread epidemic of COVID-19 has caused millions of deaths and profoundly affected the global medical landscape. Studies on COVID-19 vaccination and related myocarditis have also increased significantly.</p><p><strong>Objective: </strong>To analyze the current status and trends of myocarditis and COVID-19 vaccine research by bibliometric and to elucidate research hotspots and frontiers.</p><p><strong>Methods: </strong>Based on the Web of Science Core Collection SCI-Expanded database, we utilize Excel 2019 and visualization analysis tools VOSviewer, Co-Occurrence13.2 (COOC13.2), Citespace, HistCite, and Scimago Graphica for analysis.</p><p><strong>Results: </strong>Our study encompassed a total of 389 relevant articles, and we observed a consistent upward trend in the number of publications over time, indicating the growing interest in this subject. Among the countries and regions contributing to this body of literature, the United States emerged as the leading publisher, with Harvard Medical School being the most prominent institution associated with these studies. Notably, Matthew E. Oster from the United States emerged as one of the prominent authors in this field. Hotspot research and frontier areas include myocarditis and the different types of COVID-19 vaccines (e.g., mRNA vaccines, adenovirus vector vaccines, inactivated vaccines), the development of new vaccines in reducing the incidence and sequelae of COVID-19 without an increased incidence of myocarditis, and relief of vaccine hesitancy.</p><p><strong>Conclusion: </strong>Research on myocarditis and the COVID-19 vaccines has grown rapidly. Our research results can help researchers grasp the current status of myocarditis related to the COVID-19 vaccine research and find new research directions in the future.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115701611287623250107074054","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: This study aims to conduct a bibliometric and visual analysis of published studies on myocarditis and coronavirus disease 2019 (COVID-19) vaccines.
Background: The widespread epidemic of COVID-19 has caused millions of deaths and profoundly affected the global medical landscape. Studies on COVID-19 vaccination and related myocarditis have also increased significantly.
Objective: To analyze the current status and trends of myocarditis and COVID-19 vaccine research by bibliometric and to elucidate research hotspots and frontiers.
Methods: Based on the Web of Science Core Collection SCI-Expanded database, we utilize Excel 2019 and visualization analysis tools VOSviewer, Co-Occurrence13.2 (COOC13.2), Citespace, HistCite, and Scimago Graphica for analysis.
Results: Our study encompassed a total of 389 relevant articles, and we observed a consistent upward trend in the number of publications over time, indicating the growing interest in this subject. Among the countries and regions contributing to this body of literature, the United States emerged as the leading publisher, with Harvard Medical School being the most prominent institution associated with these studies. Notably, Matthew E. Oster from the United States emerged as one of the prominent authors in this field. Hotspot research and frontier areas include myocarditis and the different types of COVID-19 vaccines (e.g., mRNA vaccines, adenovirus vector vaccines, inactivated vaccines), the development of new vaccines in reducing the incidence and sequelae of COVID-19 without an increased incidence of myocarditis, and relief of vaccine hesitancy.
Conclusion: Research on myocarditis and the COVID-19 vaccines has grown rapidly. Our research results can help researchers grasp the current status of myocarditis related to the COVID-19 vaccine research and find new research directions in the future.
期刊介绍：
Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research.
Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
